Search Results - "Fontanillas, M."

Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice by Blancas, I., Fontanillas, M., Conde, V., Lao, J., Martínez, E., Sotelo, M. J., Jaen, A., Bayo, J. L., Carabantes, F., Illarramendi, J. J., Gordon, M. M., Cruz, J., García-Palomo, A., Mendiola, C., Pérez-Ruiz, E., Bofill, J. S., Baena-Cañada, J. M., Jáñez, N. M., Esquerdo, G., Ruiz-Borrego, M.

“…Introduction This study aimed to describe the efficacy of fulvestrant 500 mg in postmenopausal women with estrogen receptor (ER)-positive advanced/metastatic…”
Get full text

Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice by Blancas, I., Fontanillas, M., Conde, V., Lao, J., Martínez, E., Sotelo, M. J., Jaen, A., Bayo, J. L., Carabantes, F., Illarramendi, J. J., Gordon, M. M., Cruz, J., García-Palomo, A., Mendiola, C., Pérez-Ruiz, E., Bofill, J. S., Baena-Cañada, J. M., Jáñez, N. M., Esquerdo, G., Ruiz-Borrego, M.

“…A sentence under ‘Results’ heading in the Abstract section was published incorrectly. The correct sentence should read as follows:…”
Get full text

PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer by Duch, J, Fuster, D, Muñoz, M, Fernández, P L, Paredes, P, Fontanillas, M, Skaltsa, K, Domènech, B, Lomeña, F, Pons, F

“…The aim of this paper was to prospectively evaluate FDG PET/CT in the assessment of metabolic response to neoadjuvant chemotherapy and correlation with tumor…”
Get full text

Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated by Bladé, J, San Miguel, J F, Fontanillas, M, Alcalá, A, Maldonado, J, García-Conde, J, Conde, E, Conzález-Brito, G, Moro, M J, Escudero, M L, Trujillo, J, Pascual, A, Rozman, C, Estapé, J, Montserrat, E

“…To analyze the outcome of patients with multiple myeloma (MM) who were potential candidates for early high-dose therapy (HDT) intensification followed by…”
Get more information

Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL by Ortega, JJ, Ribera, JM, Oriol, A, Bastida, P, Gonzalez, ME, Calvo, C, Egurbide, I, Hernandez Rivas, JM, Rivas, C, Alcala, A, Besalduch, J, Macia, J, Gardella, S, Carnero, M, Lite, JM, Casanova, F, Martinez, M, Fontanillas, M, Feliu, E, San Miguel, JF, PETHEMA Group, Spanish Society of Hematology. Programa para el Estudio y Tratamiento de las Hemopatias Malignas

“…Haematology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. jmribera@ns.hugtip.scs.es BACKGROUND AND OBJECTIVES: To evaluate the…”
Get full text

Maintenance treatment with interferon alpha-2b in multiple myeloma : A prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology) by BLADE, J, SAN MIGUEL, J. F, ROZMAN, C, ESTAPE, J, MONTSERRAT, E, ESCUDERO, M. L, FONTANILLAS, M, BESALDUCH, J, GARDELLA, S, ARIAS, J, GARCIA-CONDE, J, CARNERO, M, MARTI, J. M

“…The objectives of the present study were to investigate whether interferon alpha (IFN) maintenance could prolong response duration and survival in patients…”
Get full text

1624PMOLECULAR PRESCREENING VS. UNSELECTED CLINICAL TRIALS FOR CANCER PATIENTS IN A TERTIARY ONCOLOGY DEPARTMENT by Alcaraz, D.W., Miralles, M.S., Gaba Garcia, L., Fernandez-Martinez, A., Gascón, P., Fontanillas, M., Vidal, L.

“…Abstract Aim: Introduction: In the recent years the use of molecular biomarker–based in patient tumour samples has become more frequent for novel agents…”
Get full text

Molecular Prescreening Vs. Unselected Clinical Trials for Cancer Patients in a Tertiary Oncology Department by Alcaraz, D.W., Miralles, M.S., Gaba Garcia, L., Fernandez-Martinez, A., Gascón, P., Fontanillas, M., Vidal, L.

Get full text

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA by Bladé, Joan, Rosiñol, Laura, Sureda, Ana, Ribera, Josep M., Díaz-Mediavilla, Joaquín, García-Laraña, José, Mateos, M. Victoria, Palomera, Luis, Fernández-Calvo, Javier, Martí, Josep M., Giraldo, Pilar, Carbonell, Félix, Callís, Manel, Trujillo, Jesús, Gardella, Santiago, Moro, M. Jesús, Barez, Abelardo, Soler, Alfons, Font, Llorenç, Fontanillas, Montserrat, Miguel, Jesús San

“…The aim of the present randomized trial was to compare high-dose therapy (HDT) with continued conventional chemotherapy in patients with multiple myeloma (MM)…”
Get full text

Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients by Bladé, J, San Miguel, J F, Fontanillas, M, Esteve, J, Maldonado, J, Alcalá, A, Brunet, S, García-Conde, J, Besalduch, J, Moro, M J, Fernández-Calvo, J, Conde, E, Font, L, Gardella, S, Carnero, M, Carbonell, F, Martí, J M, Hernández-Martín, J, Ortega, F, Besses, C, Ribera, J M, Trujillo, J, Escudero, M L, Rozman, C, Estapé, J, Montserrat, E

“…Melphalan and prednisone (MP) has been the standard treatment for multiple myeloma (MM) for the last 30 years. Combination chemotherapy at conventional doses…”
Get more information

CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology) by Montserrat, E, García-Conde, J, Viñolas, N, López-Guillermo, A, Hernández-Nieto, L, Zubizarreta, A, Maldonado, J, Alcalá, A, Faura, M V, Llorente, A, Bladé, J, Fontanillas, M, Estapé, J

“…From May 1985 to May 1989, 175 patients with previously untreated aggressive non-Hodgkin's lymphoma were randomized to receive CHOP or ProMACE-CytaBOM…”
Get more information

Assessment of Treatment Response with Fulvestrant (F) 500 Mg in Standard Clinical Practice Through a Retrospective Study: Nct01509625 by Blancas, I., Fontanillas, M., Conde Herrero, V., Lao, J., Martinez de Dueñas, E., Sotelo Lezama, M., JaÉn-Morago, A., Bayo, J.L., Carabantes, F., Illaramendi, J.J., Gordón, M., Ruiz-Borrego, M., Cruz, J., García-Palomo, A., Mendiola, C., Perez-Ruiz, E., Cañada, J.M. Baena, Martínez, N., Esquerdo, G., Bofill, J. Salvador

Get full text

362PASSESSMENT OF TREATMENT RESPONSE WITH FULVESTRANT (F) 500 MG IN STANDARD CLINICAL PRACTICE THROUGH A RETROSPECTIVE STUDY: NCT01509625 by Blancas, I., Fontanillas, M., Conde Herrero, V., Lao, J., Martinez de Dueñas, E., Sotelo Lezama, M., JaÉn-Morago, A., Bayo, J.L., Carabantes, F., Illaramendi, J.J., Gordón, M., Ruiz-Borrego, M., Cruz, J., García-Palomo, A., Mendiola, C., Perez-Ruiz, E., Cañada, J.M. Baena, Martínez, N., Esquerdo, G., Bofill, J. Salvador

“…Abstract Aim: After CONFIRM study results, fulvestrant 500 mg (F500) became one of the standard treatments for patients with oestrogen receptor (ER+)…”
Get full text

Chemotherapeutic options in chronic lymphocytic leukemia : a meta-analysis of the randomized trials

Get full text

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients by Casassus, P, Gibson, J, Joshua, DE, Matthews, J, Diaz, JC, Gertz, MA, Kyle, R, Leong, T, Oken, MM, Fritz, E, Ludwig, H, Corrado, C, Lastiri, F, Peest, D, Grosbois, B, Vela-Ojeda, J, Avvisati, G, Mandelli, F, Petrucci, MT, Capnist, G, Child, JA, Drayson, MT, Dunn, J, MacLennan, I, Mellstedt, H, Osterborg, A, Rodjer, S, Turesson, I, Westin, J, Bergsagel, D, Browman, GP, Shustik, C, Zee, B, Hjorth, M, Holmberg, E, Alison, R, Clarke, M, Elphinstone, P, Evans, V, Gray, R, Hicks, C, James, S, MacKinnon, L, Peto, R, Richards, S, Wheatley, K, Blade, J, Fontanillas, M, San Miguel, J, Aitchison, R, Newland, AC, Cunningham, D, Malpas, J, Powles, RL, Montuoro, A, Jacobson, J, Salmon, S

“…Many randomized trials have evaluated α‐interferon as myeloma therapy, some suggesting a benefit and others not. Most were too small to give reliable answers,…”
Get full text

Prognostic Significance of the Detection of Circulating Malignant Cells by Reverse Transcriptase-Polymerase Chain Reaction in Long-Term Clinically Disease-free Melanoma Patients by MELLADO, B, GUTIERREZ, L, CASTEL, T, COLOMER, D, FONTANILLAS, M, CASTRO, J, ESTAPE, J

“…The purpose of this study was to assess the prognostic significance of the detection of circulating melanoma cells by reverse transcriptase-PCR in long-term…”
Get full text

Tyrosinase mRNA in Blood of Patients With Melanoma Treated With Adjuvant Interferon by Mellado, Begoña, Del Carmen Vela, Maria, Colomer, Dolors, Gutierrez, Lorena, Castel, Teresa, Quintó, Llorenç, Fontanillas, Montserrat, Reguart, Noemi, Domingo-Domènech, José M, Montagut, Clara, Estapé, Jordi, Gascón, Pedro

“…To evaluate the clinical significance of the detection of circulating melanoma cells in patients treated with adjuvant interferon and to determine their…”
Get full text

774 Alternating VCMP/VBAP at standard doses (SD) vs. VCMP/VBAP at intermediate doses (ID) as initial treatment of multiple myeloma (MM) by Bladé, J., San Miguel, J.F., Escudero, M.L., Fontanillas, M.

“…In a previous PETHEMA study we have shown that VCMP/VBAP increases response rate in MM when compared with melphalan/prednisone. The aim of the present study…”
Get full text

Treatment of Multiple Myeloma in Elderly People: Long-term Results in 178 Patients by BLADÉ, JOAN, MUÑOZ, MONTSERRAT, FONTANILLAS, MONTSERRAT, SAN MIGUEL, JESÚS, ALCALÁ, ANTONIO, MALDONADO, JUAN, BESSES, CARLES, JESÚS MORO, MARÍA, GARCÍA-CONDE, JAVIER, ROZMAN, CIRIL, MONTSERRAT, EMILI, ESTAPÉ, JORDI

“…The purposes of the present study have been to analyse the presenting features, response to therapy and survival of myeloma patients aged 70 years or more, in…”
Get full text

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group by Geisler, C, Hansen, MM, Yeap, BY, Wiernik, P, Binet, JL, Chastang, C, Dighiero, G, Travade, P, Jaksic, B, Brugiatelli, M, Kimby, E, Catovsky, D, Hamblin, T, Richards, S, Bosch, F, Fontanillas, M, Montserrat, E, Alison, R, Clarke, M, Duong, H, Elphinstone, P, Evans, V, Godwin, J, Gray, R, Greaves, E, Hicks, C, James, S, Mead, G, Peto, R, Wheatley, K

“…The randomized trials that evaluate the timing and intensity of initial chemotherapy for chronic lymphocytic leukemia (CLL) have, in general, been too small to…”
Get full text